Core B: Outreach, Ascertainment, and Data Collection

项目摘要/摘要：核心B(外联、确定和数据收集核心) 核心B的总体目标是提供基础设施和支持，以确定和收集 4000名非裔美国人(AA)、4000名西班牙裔/拉丁裔美国人(HL)的表型数据和生物样本 来自美国和非洲的5000名非洲人(AF)。核心B收集的表型数据将发送到核心E 并由Core C用于裁决和协调，同时采集血液、血浆和RNA样本 将被送往迈阿密大学约翰·P·赫斯曼人类基因组研究所(HIHG) (Um)，用于项目1和2的DNA基因分型以及FUS 2.0和生物标记物的未来WGS研究 表达研究(核心D)。核心B的工作将为常见和罕见的工作提供必要的材料 在项目1和2的分配研究中对祖先群体的变异分析和发现。 AIM 1将在美国4个地点和9个AF地点招募和确定AA和HL参与者。AF赛场在8个地点 不同国家，非洲痴呆症联盟(AFDC)的所有成员。尼日利亚伊巴丹大学， 将是AFDC其他地点的主要协调地点。我们将确定约13,000名个人/参与者 包括AA(n=4,000)、HL(n=4,000)和AF(n=5,000)。具体目标2. 我们将收集临床、神经认知测试、血液样本和关于再生障碍性贫血(n=4,000)、白血病(n=4,000)和 房颤(n=5,000)参与者。将收集DNA、RNA和血浆的试管。这项研究将提供一个资源 用于未来AA、AF和HL患者的AD研究。

PROJECT SUMMARY/ABSTRACT: CORE B (Outreach, Ascertainment and Data Collection Core) The overall goal of Core B is to provide the infrastructure and support for the ascertainment and collection of phenotypic data and biological samples on 4000 African Americans (AA), 4000 Hispanic/Latinx Americans (HL) and 5000 Africans (AF) from the US and Africa. The phenotypic data gathered by Core B will sent to Core E and used for adjudication and harmonization by Core C, while the blood, plasma, and RNA samples collected by Core B will be sent to the John P. Hussman Institute for Human Genomics (HIHG) at the University of Miami (UM), used for DNA genotyping for Projects 1 and 2 and future WGS studies in FUS 2.0 and biomarkers and expression studies (Core D). The work of Core B will provide the necessary materials for both common and rare variant analysis and discovery in ancestral populations in the imputation studies in Projects 1 and 2. Specific Aim 1 will recruit and ascertain AA and HL participants in four US and nine AF sites. The AF sites are in eight different countries, all members of the African Dementia Consortium (AfDC). The University of Ibadan, Nigeria, will be the primary coordinating site for the other AfDC sites. We will ascertain ~13,000 individuals/participants (6,500 cases and 6,500 controls) consisting of AA (n=4,000), HL (n=4,000) and AF (n=5,000). Specific Aim 2. We will collect clinical, neurocognitive testing, blood samples and metadata on AA (n=4,000), HL (n=4,000) and AF (n=5,000) participants. Tubes for DNA, RNA and plasma will be collected. This study will provide a resource for future studies in AD in AA, AF and HL patients.